Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: A case-control study

Clinical Microbiology and Infection

Volumn 16, Issue 9, 2010, Pages 1375-1377

  De Castro, N ^a   Xu, F ^a   Porcher, R ^a   Pavie, J ^a   Molina, J M ^a   Peraldi, M N ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Lymphocyte count; Pneumocystis jirovecii; Prophylaxis; Renal transplantation

Indexed keywords

COTRIMOXAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COUGHING; DRUG MEGADOSE; DYSPNEA; FEMALE; FEVER; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG LAVAGE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; TROPHOZOITE;

MAMMALIA; PNEUMOCYSTIS JIROVECII;

EID: 77956116676     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03143.x     Document Type: Article

References (13)

1. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001, 33:1397-1405.
2. Di Cocco P, Orlando G, Bonanni L. A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc 2009, 41:1201-1203.
3. Gordon SM, LaRosa SP, Kalmadi S. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999, 28:240-246.
4. Lufft V, Kliem V, Behrend M, Pichlmar R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation: impact of immunosuppression. Transplantation 1996, 62:421-423.
5. Arend SM, Westendorp RGJ, Kroon FP. Rejection treatment and CMV infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996, 22:920-925.
6. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jirovecii pneumonia. Transplantation 2009, 88:135-141.
7. Radisic M, Lattes R, Chapman JF. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003, 5:84-93.
8. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997, 175:901-904.
9. Schmoldt S, Schuhegger R, Wendler T. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008, 46:966-971.
10. Hauser PM, Sudre P, Nahimana A, Francioli P. Prophylaxis failure is associated with a specific Pneumocystis carinii genotype. Clin Infect Dis 2001, 33:1080-1082. the study group
11. Su YS, Lu JJ, Perng CL, Chang FY. Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2008, 41:478-482.
12. De Castro N, Neuville S, Sarfati C. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005, 36:879-883.
13. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995. Chest 2000, 118:704-711.